Search Results
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Enhanced safety: Demonstrates a cytopenia-sparing profile, with no dose-limiting toxicities observed up to 24 mg/kg and receptor occupancy >90% at ≥1.28 mg/kg, supporting a broad therapeutic window. Robust immune activation: Engineered
More news about: HanchorBio Inc.
Oct 20, 2025, 04:30 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
with advanced solid tumors regardless of CLDN18.2 expression receive ATG-022 (0.3-3.0 mg/kg Q3W) to evaluate safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥IHC 1+, 1%) patients are treated at 1.8 or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety.
More news about: Antengene Corporation Limited
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
regardless of CLDN18.2 expression receive ATG-022 once every three weeks (0.3-3.0 mg/kg Q3W) to evaluate the safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥ IHC 1+, 1%) patients are treated at 1.8 mg/kg or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety.
More news about: Antengene Corporation Limited
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
As of the data cutoff date, 72 patients with advanced solid tumors treated across 6 dose levels (DL1-6, 1-45 mg/kg); 72.2% remain on treatment. Heavily pretreated population: over 51% received prior immuno-oncology (IO) therapies. Median
More news about: CStone Pharmaceuticals
Oct 19, 2025, 19:30 ET IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1
More news about: Astellas Pharma Inc.
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
immunotherapy. Patients with prior anti-EGFR therapy were excluded. Subcutaneous amivantamab was administered every three weeks (Q3W) at 2400 mg, or 3360 mg for patients weighing 80 kg or more. The primary endpoint is overall response rate (ORR), assessed by blinded independent central review (BICR)
More news about: Johnson & Johnson
Oct 19, 2025, 03:00 ET 普眾發現在2025年歐洲腫瘤內科學會（ESMO）上公布其抗MUC18 ADC（AMT-253）用於晚期惡性黑色素瘤及其他實體瘤的初步積極數據
截至2025年9月8日，已有170例受試者的數據可供安全性分析。這些受試者接受每三周一次（Q3W）的AMT-253治療，劑量范圍為1.6至5.6 mg/kg。入組的受試者主要為惡性黑色素瘤、子宮內膜癌、宮頸鱗癌和子宮平滑肌肉瘤。入組的惡性黑色素瘤既往接受過1-7線的治療，在未經MUC18表達篩選、且經多線治療惡性黑色素瘤受試者中觀察到積極的療效信號。所有的惡性黑色素瘤受試者的客觀緩解率（ORR）為28.6%（16/56，包括15例已確認的部分緩解，以及1例尚未確認部分緩解，仍在繼續治療）。在未經化療治療的惡性黑色素瘤中，皮膚型、肢端型和黏膜型的ORR分別為35%（7/20，均已確認）、50%（5/10，包括4例已確認，以及1例尚未確認，仍在繼續治療）和33.3%（1/3，已確認），初步的中位無
More news about: 普眾發現
Oct 19, 2025, 03:00 ET Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
September 8th, 2025, safety data are available for 170 patients who have received AMT-253 once every three weeks (Q3W) at doses ranging from 1.6 to 5.6 mg/kg. Primary tumor types are melanoma, endometrial cancer, cervical squamous cancer and uterine leiomyosarcoma. In heavily pretreated melanoma patients,
More news about: Multitude Therapeutics, Inc.
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
(proteasome inhibitor, immunomodulatory agent, and CD38 monoclonal antibody). By the screening period, his serum free light chain level had reached 10,374.86 mg/L. The patient underwent two CAR-T cell infusions approximately two months apart: he first received low-dose lymphodepletion and a relatively lower dose
More news about: CARsgen Therapeutics
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV. Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD
More news about: Astellas Pharma Inc.
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Pomerantz LLP
Oct 18, 2025, 06:00 ET Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
the ALKOVE-1 clinical trial as of a data cutoff date of August 7, 2025. The majority (32/34) of patients received the recommended Phase 2 dose of 150 mg once daily. Patients were ALK TKI-naïve (38%, 13/34) or ALK TKI pre-treated (62%, 21/34), and 62% (21/34) of patients had received prior chemotherapy.
More news about: Nuvalent, Inc.
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE)
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
dosages: 7 mg and 14 mg.5,6 Rybelsus® is currently commercially marketed in 45 countries. 2.4 million people have been prescribed Rybelsus® worldwide.7 What is RYBELSUS®? RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is
More news about: Novo Nordisk
Oct 17, 2025, 10:00 ET 普眾發現在2025年歐洲腫瘤內科學會（ESMO）上公佈其抗CD44v9 ADC（AMT-116）用於晚期EGFR野生型非小細胞肺癌（NSCLC）及其他晚期實體瘤的初步積極數據
截至2025年7月17日，已有164例受試者的數據可供分析安全性。這些受試者接受每兩週一次（Q2W）的AMT-116治療，劑量範圍為1.5至5.0 mg/kg。入組的受試者主要為 NSCLC、鼻咽癌、肛門鱗癌和唾液腺癌等。入組的EGFR野生型NSCLC既往接受過1-5線的治療，在未經CD44v9表達篩選、且經多線治療的EGFR野生型NSCLC受試者中觀察到積極的療效信號。在≥3.0mg/kg的EGFR野生型NSCLC受試者的客觀緩解率（ORR）為40%（6/15），疾病控制率（DCR）為93%（14/15）。在5.0 mg/kg的EGFR野生型NSCLC受試者的ORR為80%（4/5），DCR為100%（5/5）。同時，在鼻咽癌、肛門癌和唾液腺癌亦看到初步療效，在≥3.0mg/kg 劑量下，ORR分別為50% (3/6),
More news about: 普眾發現
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
NSCLC at dose levels >3 mg/kg. Among five EGFR Wild-type NSCLC patients at 5.0 mg/kg, ORR was 80% (4/5) and DCR was 100% (5/5). Preliminary antitumor activity was also observed in patients with NPC, anal carcinoma and salivary gland cancer at >3mg/kg, with ORRs of 50% (3/6), 60% (3/5)
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
were seen. Mandatory preventive measures for neutropenia have been added in ongoing global studies. For patients receiving 2.5 mg/kg (Days 1 and 8 every 3 weeks), 55% (11 of 20) showed a confirmed response, with a median progression-free survival of 5.4 months. Confirmed responses
More news about: SystImmune, Inc.
Oct 17, 2025, 08:30 ET Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
INGREZZA (40 mg or 80 mg capsules) followed by a four-week washout. Dosing was initiated at 40 mg/day in all participants, with escalation to 80 mg/day at Week 4 based on effectiveness and tolerability. Dose reduction to 40 mg was allowed in participants who could not tolerate the 80 mg dose. Patients
More news about: Neurocrine Biosciences, Inc.
Oct 17, 2025, 08:00 ET Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting
announced additional data from its pivotal Phase 3 SynAIRgy and LunAIRo trials evaluating the investigational drug, AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), which will be presented as a core interactive session and two late-breaking rapid fire oral and poster presentations at the CHEST Annual Meeting
More news about: Apnimed, Inc.
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
of 200 mg twice daily or 150 mg twice daily, reduce the Verzenio dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the Verzenio dose to 50 mg twice
More news about: Eli Lilly and Company
Oct 17, 2025, 07:00 ET CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin Cancers In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to
More news about: Insmed Incorporated
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
YUFLYLMA was first introduced in the U.S. market in July 2023 and is currently available as 20mg, 40mg, and 80mg solution for injection in prefilled syringes and as 40mg and 80mg solution for injection in autoinjectors. Celltrion offers adalimumab-aaty in both branded and unbranded versions,
More news about: Celltrion USA
Oct 17, 2025, 00:28 ET Industrial Gases Market to Reach USD 195.36 Billion by 2032, Growing At An 7.44% CAGR - Credence Research
S.p.A. (Italy) Gulf Cryo (Kuwait) nexAir, LLC (United States) Goyal MG Gases Pvt. Ltd. (India) Universal Industrial Gases, Inc. (United States) INOX Air Products Ltd.
More news about: Credence Research Inc.
Oct 16, 2025, 10:21 ET The King of the Monsters Meets the King of Energy: C4 Ultimate Energy® x Godzilla Arrives
experience. Launching November 3 on Godzilla Day, C4 Ultimate Energy Sour Blue Razzilla delivers a bold surge of tangy blue raspberry flavor with 300mg of caffeine, zero sugar, and the brand's proprietary Tri-Stim Experience (Caffeine, TeaCrine®, Dynamine®) for sustained energy
More news about: Nutrabolt
Oct 16, 2025, 10:15 ET Infection Control Market worth $77.67 billion by 2030 with 6.3% CAGR | MarketsandMarkets™
several advantages over large-molecule or biologic drugs. They can be designed to provide strong therapeutic effects at very small doses, often below 10 mg or even at microgram levels. The reduced quantity requirements, coupled with improvements in chemical manufacturing technologies, make synthetic APIs
More news about: MarketsandMarkets